協和キリン（4151） – Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2022 First Quarter

May 10, 2022Kyowa Kirin Co., Ltd.Appendix to the Consolidated Financial Summary (IFRS)Fiscal 2022 First Quarter(January 1, 2022 – March 31, 2022)–These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo StockExchange on May 10, 2022 for the first three months of Fiscal 2022, from January 1, 2022 to March 31, 2022.This document is an English translation of the Japanese-language original. The statements, including earnings forecasts, contained in thesematerials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable bymanagement. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from theseprojections for a wide variety of reasons.- Figures presented in these materials have been rounded to the nearest tenth.- Figures inside parenthesis presented in these materials indicate negative values. IndexⅠ．Consolidated Financial Results1. Trends in consolidated profit2. Revenue by regional control function3. Revenue by location of customer4.Capital expenditures (property, plant and equipment) and intangible assetsinvestment5. Depreciation and amortizationⅡ．Consolidated Statement of Cash Flows Ⅲ．Revenue from Main ProductsⅣ．R&D Pipeline Page12222236The average exchange rates for each period were as follows:FY 2021 resultsUnit: YenFY 2022forecastsJan – Mar Jan – Jun Jan – Sep Jan – Dec Jan – Mar Jan – Dec11015017.1FY 2022results10514316.110714716.410814916.610915016.911415418.0USDGBPCNYContactKyowa Kirin Co., Ltd.Corporate Communications DepartmentTel +81 3 5205 7206FY2021-2025Medium TermBusiness PlanFinancial KPIs- 10% or higher-25% or higherTarget of 40%10% or higher23%27%22%-22%19%48%26%28%21%30%——-380.09.3%(82.0)298.078.4%18.4%3.067.017.6%66.0(13.0)19.7%53.013.9%98.64100.1348.0047.97.1The “★” symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.Unit: Billions of yenFY 2021 resultsFY 2022 resultsFY 2022 forecastsJan – MarJan – JunJan – SepJan – DecJan – MarJan – DecProgressChangeamountRate ofchangeRevenue81.1165.0254.0-(22.4)58.772.4%-(41.2)123.875.0%-(64.1)189.974.8%(31.7)(67.2)(104.1)(145.6)(36.1)14%(164.0)Research and development expenses(12.2)(26.5)(40.2)(57.7)(13.6)12%(70.0)★ R&D expense ratio15.0%16.1%15.8%16.4%15.5%- Target of 18-20%Ⅰ. Consolidated Financial Results1. Trends in consolidated profit★ CAGR (compared to FY 2020)Cost of sales Gross profitGross profit to revenue ratio Selling, general and administrativeexpensesShare of profit (loss) of investmentsaccounted for using equity methodCore operating profit★ Core operating profit ratioOther incomeOther expensesFinance income (costs)Profit before taxIncome tax expenseRatio of income tax burdenProfitProfit to revenue ratioEPS (¥/share)Core EPS (¥/share)*1Annual dividend (¥/share)★Dividend payout ratio (%)*2★ROE (%)RevenueCost of salesGross profitGross profit to revenue ratioSelling, general and administrativeexpensesShare of profit (loss) of investmentsaccounted for using equity methodCore operating profit★ Core operating profit ratioOther incomeOther expensesFinance income (costs)Profit before taxIncome tax expenseProfit0.615.519.1%0.2(0.2)0.616.2(3.2)20.0%12.915.9%24.0524.0081.1(22.4)58.772.4%0.615.519.1%0.2(0.2)0.616.2(3.2)12.90.930.918.8%0.4(1.1)0.931.1(6.0)19.4%25.115.2%46.6747.7583.9(18.9)65.077.5%0.315.418.4%0.1(0.9)0.314.9(2.8)12.21.346.818.4%0.7(5.8)0.141.9(9.0)21.4%32.913.0%61.2568.6288.9(22.9)66.174.3%0.415.917.8%0.4(4.7)(0.8)10.8(3.0)7.88.8%Profit to revenue ratio15.9%14.5%19.8%18.3%87.8-(22.2)65.674.7%1.417.319.8%0.4(0.2)1.218.7(2.7)14.3%16.018.3%29.8529.5287.8(22.2)65.674.7%1.417.319.8%0.4(0.2)1.218.7(2.7)16.06.60.26.9——(4.4)(1.4)0.81.80.2(0.0)0.62.60.63.15.805.516.60.26.9(4.4)(1.4)0.81.80.2(0.0)0.62.60.63.1—-8%(1)%12%126%12%95%14%92%16%(17)%24%8%(1)%12%14%12%126%12%95%14%92%16%(17)%24%————352.210.6%(87.8)264.475.1%4.665.718.6%1.0(6.6)(0.0)60.1(7.7)12.8%52.314.9%97.43106.5746.0043.27.398.3(23.7)74.575.8%3.318.919.2%0.2(0.8)(0.1)18.21.319.4- 1 -*1 Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting “other income,” “other expenses” and the related “income tax expense” from “profit”) by the average number of shares during the period.*2 Dividend payout ratio is shown based on core EPS.FY 2021 resultsJan – MarApr – JunJul – SepOct – DecJan – MarUnit: Billions of yenFY 2022 resultsChangeamountRate ofchange(31.7)(35.6)(36.9)(41.5)(36.1)Research and development expenses(12.2)(14.3)(13.7)(17.4)(13.6)★ R&D expense ratio15.0%17.0%15.4%17.8%15.5%2. Revenue by regional control functionJapanEMEANorth AmericaAsia/OceaniaOthersJapanInternationalAmericasEuropeAsiaOthersOf which, the U.S.Total consolidated revenue81.1165.0254.0352.287.8***Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin structure (a global managementstructure with axes combining four regions – Japan, North America, EMEA, and Asia/Oceania – and the functions needed by a global specialty pharmaceutical company).EMEA consists of Europe, the Middle East, Africa, etc.Others consists of revenue from technology out-licensing, original equipment manufacturing, etc.3. Revenue by location of customerFY 2021 resultsFY 2022 resultsFY 2022 forecastsUnit: Billions of yenJan – MarJan – JunJan – SepJan – DecJan – MarJan – DecProgressChangeamount114.9156.9(3.8)149.039.215.912.06.97.176.734.625.914.313.654.239.822.123.078.856.128.432.135.420.714.57.29.84.82.50.42.76.6100.962.526.641.0380.024%21%23%27%24%23%FY 2021 resultsFY 2022 resultsFY 2022 forecastsUnit: Billions of yenJan – MarJan – JunJan – Sep Jan – DecJan – MarJan – DecPercentage ofconsolidatedrevenuePercentage ofconsolidatedrevenuePercentage ofconsolidatedrevenue40.940.320.620.011.38.20.079.985.143.441.724.417.10.1119.1134.969.967.938.226.70.1162.0190.3102.299.353.434.50.246%54%29%28%15%10%0%42%58%32%31%15%10%0%154.5225.5133.561.031.00.0Total consolidated revenue81.1165.0254.0352.2100%87.8100%380.0100%* Revenue by location of customer is classified by region or country based on location of customer.4. Capital expenditures (property, plant and equipment) and intangible assets investmentFY 2021 resultsFY 2022 resultsUnit: Billions of yenFY 2022forecastsJan – MarJan – JunJan – SepJan – DecJan – MarJan – DecCapital expenditures (property, plant and equipment)Intangible assets investmentTotal*Acquisitions of right-of-use assets are not included.5. Depreciation and amortizationDepreciation (property, plant and equipment)Amortization (intangible assets)Total2.01.63.72.81.94.6FY 2021 resultsFY 2022 resultsUnit: Billions of yenFY 2022forecastsJan – MarJan – JunJan – SepJan – DecJan – MarJan – DecⅡ. Consolidated Statement of Cash FlowsFY 2021 resultsUnit: Billions of yenFY 2022 resultsJan – MarJan – JunJan – SepJan – DecJan – MarChange amountCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesEffect of exchange rate changes on cash and cash equivalentsNet increase (decrease) in cash and cash equivalentsCash and cash equivalents at beginning of periodCash and cash equivalents at end of period14.4(4.6)(13.5)0.4(3.3)287.0283.823.0(1.9)(14.3)(1.1)5.7287.0292.886.5(11.4)(28.4)1.348.1287.0335.18.8(4.6)(13.2)0.4(8.6)335.1326.536.950.928.227.313.59.10.09.113.222.311.28.319.51.81.02.82.91.74.641%59%35%16%8%0%18.311.730.012.17.019.0(5.6)(0.0)0.20.0(5.4)48.142.74.711.115.88.35.613.981.2(10.8)(27.6)0.643.4287.0330.42.82.95.75.53.79.2- 2 -Ⅲ. Revenue from Main ProductsProduct nameDarbepoetin Alfa Injection Syringe [KKF]napaJRituximab BS [KHK]NespDuvroqRegparaOrkediaRocaltrolOnglyzaConielG-LastaFentosPoteligeoRomiplateAllelockPatanolDovobetLumicefNouriastHARUROPIDepakeneCrysvitaCrysvitaPoteligeoNourianzAbstralPecfentMoventigAdcal-D3NespRegparalanoitanretnITechnology out-licensingNeulasta/PeglastaGranTechnology out-licensingFY 2021 resultsFY 2022 resultsJan – MarJan – Jun Jan – SepJan – DecJan – MarJan – DecProgressUnit: Billions of yenFY 2022forecastsChangeamount(0.1)3.1(1.1)16.41.92.94.011.016.722.313.821.229.40.531.50.51.54.61.53.01.31.80.95.32.84.87.83.51.44.21.31.73.31.37.01.94.01.91.41.33.24.62.63.09.17.11.42.17.12.34.62.02.81.58.14.96.39.25.22.16.42.22.75.11.53.16.32.92.02.14.96.74.04.92.62.99.93.26.22.73.92.011.27.38.010.77.22.98.73.13.67.21.64.58.53.92.83.06.47.45.36.316.411.724.516.80.84.41.10.52.20.71.20.67.10.80.52.52.22.41.81.70.71.80.80.82.00.14.21.11.41.00.70.71.91.01.72.17.74.70.710.05.52.410.03.05.12.23.31.99.76.63.97.43.08.45.53.022.56.66.74.23.22.66.63.74.76.734.30.9(0.2)0.10.0(0.2)(0.0)(0.0)(0.0)(0.1)(0.5)(4.7)0.20.0(0.1)0.20.00.51.10.2(0.4)(0.0)(1.3)0.20.00.30.40.82.70.927%27%20%21%22%25%24%27%23%24%24%26%22%37%47%23%22%21%14%28%19%12%21%19%17%21%24%23%25%28%26%36%31%22%10.0(0.5)1.016.335.422.26.0 105.255.111.078.315.31.05.50.20.72.10.71.50.66.60.80.52.61.52.96.51.50.61.90.60.81.50.63.21.01.81.00.60.61.62.21.31.34.93.8* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions and technology out-licensing is classifiedOf which, Benralizumab royaltyas Japan or International (other than Japan) based on the location of the customer.* Revenue from main products does not include revenue from the Early Access Program (EAP).* Revenue listed as “Technology out-licensing” specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based onlicensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compounds or the use of technology, etc.* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).- 3 -Ⅲ. Revenue from Main ProductsProduct nameDarbepoetin Alfa Injection Syringe [KKF]napaJRituximab BS [KHK]NespDuvroqRegparaOrkediaRocaltrolOnglyzaConielG-LastaFentosPoteligeoRomiplateAllelockPatanolDovobetLumicefNouriastHARUROPIDepakeneCrysvitaCrysvitaPoteligeoNourianzAbstralPecfentMoventigAdcal-D3NespRegparalanoitanretnITechnology out-licensing16.319.219.623.322.2Neulasta/PeglastaGranTechnology out-licensingOf which, Benralizumab royalty* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions andtechnology out-licensing is classified as Japan or International (other than Japan) based on the location of the customer.* Revenue from main products does not include revenue from the Early Access Program (EAP).* Revenue listed as “Technology out-licensing” specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtainedbased on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compoundsor the use of technology, etc.* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).Unit: Billions of yenFY 2021 resultsFY 2022 resultsJan – Mar Apr – Jun Jul – SepOct – DecJan – MarChangeamount1.05.50.20.72.10.71.50.66.60.80.52.61.52.96.51.50.61.90.60.81.50.63.21.01.81.00.60.61.62.21.31.34.93.81.05.50.40.82.50.81.60.77.21.00.52.71.31.91.22.00.72.30.80.91.90.73.81.02.20.90.80.71.62.31.31.74.13.41.05.60.80.72.50.81.50.77.41.00.52.82.11.41.51.70.72.20.81.01.80.14.01.12.21.00.70.81.72.21.41.97.34.61.15.61.20.72.70.91.60.78.21.00.53.12.41.81.52.00.82.31.00.92.10.24.31.52.31.00.80.91.50.71.31.48.05.10.84.41.10.52.20.71.20.67.10.80.52.52.22.41.81.70.71.80.80.82.00.14.21.11.41.00.70.71.91.01.72.17.74.7(0.1)(1.1)0.9(0.2)0.10.0(0.2)(0.0)0.5(0.0)(0.0)(0.1)0.7(0.5)(4.7)0.20.0(0.1)(0.5)0.20.00.56.01.10.2(0.4)(0.0)(1.3)0.20.00.30.40.82.70.9- 4 -Ⅲ. Revenue from Main ProductsRevenue of three global strategic productsFY 2021 resultsFY 2022 resultsFY 2022 forecastsJan – MarJan – JunJan – SepJan – DecJan – MarJan – DecProgressChangeamountProduct nameCrysvitaJapanNorth AmericaEMEAAsia/OceaniaPoteligeoJapanNorth AmericaNouriast/NourianzEMEAJapanNorth America Total of three global strategic productsProduct nameCrysvitaJapanNorth AmericaEMEAAsia/OceaniaPoteligeoJapanNorth AmericaNouriast/NourianzEMEAJapanNorth America Total of three global strategic productsUnit: Billions of yen115.210.021%19%105.221%24.51.915.07.615.08.46.619%24%22%12%19%21%17%21%24.252.882.0116.031.8154.7Unit: Billions of yenFY 2021 resultsFY 2022 resultsJan – MarApr – JunJul – SepOct – DecJan – MarChangeamount- – 17.81.511.74.53.60.52.60.62.91.91.017.81.511.74.53.60.52.60.62.91.91.038.83.325.79.77.90.95.81.16.14.21.921.01.914.05.24.30.53.20.63.32.31.060.25.140.314.80.012.41.59.21.89.46.43.121.41.814.55.10.04.50.53.30.63.32.21.185.57.257.720.60.017.32.012.72.613.28.74.525.32.117.55.80.04.90.53.50.83.82.31.524.22.015.86.30.04.70.53.30.92.91.81.124.22.015.86.30.04.70.53.30.92.91.81.1- – (0.0)(0.1)6.40.54.11.80.01.10.70.40.10.27.56.40.54.11.80.01.10.70.40.10.27.5(0.0)(0.1)24.228.629.234.031.8* Revenue is classified based on consolidated revenue from regional control functions.* Revenue from main products does not include revenue from the Early Access Program (EAP).- 5 -Nephrologyantibodyproteinsmall molecule◎ New Molecular EntityUpdated since Dec. 31, 2021Updated since Dec. 31, 2021StageMechanism of ActionIndicationAreaPhⅠPhⅡPhⅢFiledApprovedⅣ．R&D PipelineCode NameGeneric NameFormulationKHK7580EvocalcetOral◎RTA 402Bardoxolone MethylOralCalcimimeticSecondary HyperparathyroidismAlport SyndromeAntioxidant InflammationModulatorDiabetic Kidney DiseaseAutosomal Dominant PolycysticKidney DiseaseKW-3357Antithrombin GammaInjectionKHK7791Tenapanor HydrochlorideOralRecombinant HumanAntithrombinPreeclampsiaNHE3 InhibitorHyperphosphatemia in Patientson DialysisOncologyCode NameGeneric NameFormulationKW-0761MogamulizumabInjectionMechanism of ActionIndicationAreaStagePhⅠPhⅡPhⅢFiledApprovedAnti-CCR4 HumanizedAntibodyMycosis Fungoides andSézary SyndromeCNAsiaJPJPJPJPJPCACNKRKWJPJPJPNANAMobilization of HematopoieticStem Cells into Peripheral Bloodfor Allogeneic Blood Stem CellTransplantationMobilization of HematopoieticStem Cells into Peripheral Bloodfor Autologous Blood Stem CellTransplantationAutomated Injection Device forDecreasing the Incidence ofFebrile Neutropenia in PatientsReceiving Cancer ChemotherapySolid TumorUrothelial carcinomaFollicular Lymphoma andMarginal Zone LymphomaFollicular LymphomaMarginal Zone LymphomaIndolent B-cell Non-Hodgkin’sLymphomaB-cell malignanciesEuropeJPNAEuropeAsiaOceaniaothersNAEuropeAsiaOceaniaJPNAAnkylosing SpondylitisAnkylosing SpondylitisSystemic SclerosisPalmoplantar PustulosisTWMYTLTLJPJPJPNAEurope- 6 -KRN125PegfilgrastimInjectionLong-ActingGranulocyte Colony-Stimulating Factor◎KHK2455OralIDO1 Inhibitor◎ME-401ZandelisibOralPI3Kδ InhibitorKHK4827BrodalumabInjectionAnti-IL-17 Receptor AFully Human AntibodyNon-radiographic AxialSpondyloarthritis◎KHK4083/AMG 451RocatinlimabInjectionAnti-OX40 Fully HumanAntibodyAtopic DermatitisAs of Mar. 31, 2022[In-House or Licensed]Remarks[Mitsubishi Tanabe Pharma]product name in Japan: Orkedia[Reata][In-House]product name in Japan:Acoalan[Ardelyx][In-House or Licensed]Remarks[In-House]POTELLIGENT®product name in Japan, U.S. andEurope: Poteligeo[Amgen K-A]product name in Japan:G-Lasta[In-House]Combination with KW-0761[In-House]Combination with avelumab[MEI Pharma]Combination with rituximabSecond line +[MEI Pharma]Third line +[MEI Pharma]Third line +[MEI Pharma]Monotherapy, combination withrituximab and combination withzanubrutinib[Amgen K-A]product name in Japan: Lumicef[In-House]POTELLIGENT®Human Antibody-ProducingTechnologyCollaboration agreement withAmgen for the development ofKHK4083/AMG 451 in all thecountries except for Japan.Immunology/AllergyCode NameGeneric NameFormulationMechanism of ActionIndicationAreaStage[In-House or Licensed]RemarksPhⅠPhⅡPhⅢFiledApprovedⅣ．R&D PipelineCentral Nervous SystemCode NameGeneric NameFormulation◎KW-6356Oral◎KHK6640InjectionAdenosine A2AReceptorAntagonist/InverseAgonistAnti–Amyloid BetaPeptide AntibodyOtherCode NameGeneric NameFormulationantibodyproteinsmall molecule◎ New Molecular EntityUpdated since Dec. 31, 2021Updated since Dec. 31, 2021Mechanism of ActionIndicationAreaPhⅠPhⅡPhⅢFiledApprovedAs of Mar. 31, 2022[In-House or Licensed]RemarksParkinson’s DiseaseJP[In-House]※ Since the development of KW-6002 for Parkinson’s Disease was discontinued in Europe, the relevant information was deleted from this table.Alzheimer’s DiseaseJPEurope[Immunas Pharma]Mechanism of ActionIndicationAreaPhⅠPhⅡPhⅢFiledApprovedKRN23BurosumabInjectionAnti-FGF23 FullyHuman AntibodyX-linked Hypophosphatemia(XLH)[In-House or Licensed]Remarks[In-House]Human Antibody-ProducingTechnologyJointly Developed withUltragenyx in US and EUproduct name in Japan, U.S. andEurope: CrysvitaStageStageTLMYCNMYSGTLTumor Induced Osteomalacia(TIO)EuropeTreatment of Adult Patients withChronic ImmuneThrombocytopenia (ITP) Who DoNot Respond Well to OtherTreatments, Such asCorticosteroids andImmunoglobulinTreatment of Adult AplasticAnemia Refractory toConventional TherapiesTreatment of Adult Patients withChronic ImmuneThrombocytopenia (ITP) WhoAre Refractory to OtherTreatments andTreatment of Adult Patients withAplastic Anemia Who AreRefractory to ConventionalTherapyAplastic Anemia Who WerePreviously Untreated withImmunosuppressive TherapyDisseminated IntravascularCoagulation, CongenitalAntithrombin DeficiencyJPAsiaEuropeWet Age-Related MacularDegenerationJPAMG531RomiplostimInjectionThrombopoietin ReceptorAgonist[Amgen K-A]product name in Japan:RomiplateKW-3357Antithrombin GammaInjectionKHK4951OphthalmicRecombinant HumanAntithrombinPhⅡ/PhⅢ[In-House]product name in Japan: Acoalan[In-House]- 7 –